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DOI 10.1016/j.ccr.2011.11.005SUMMARYTumor heterogeneity has been implicated in tumor growth and progression as well as resistance to therapy.
We present an example of genetic heterogeneity in human malignant brain tumors in which multiple closely
related driver genes are amplified and activated simultaneously in adjacent intermingled cells. We have
observed up to three different receptor tyrosine kinases (EGFR, MET, PDGFRA) amplified in single tumors
in different cells in a mutually exclusive fashion. Each subpopulation was actively dividing, and the genetic
changes resulted in protein production, and coexisting subpopulations shared common early genetic muta-
tions indicating their derivation from a single precursor cell. The stable coexistence of different clones within
the same tumor will have important clinical implications for tumor resistance to targeted therapies.INTRODUCTION
Tumor heterogeneity is defined by the presence of cell subpop-
ulations harboring distinct genetic or gene expression profiles
with distinct biologic properties (Marusyk and Polyak, 2010)
and plays a crucial role in tumor progression and resistance to
therapy (Gerlinger and Swanton, 2010). Studies have shown
that tumor heterogeneity affects most critical tumor properties
such as metastatic potential (Yachida et al., 2010), acquired
resistance to therapy (Yip et al., 2009), and angiogenic potential
(Jain et al., 2007). Whereas regional genetic heterogeneity
within single tumors is well-described and termed clonal evolu-
tion, it is generally assumed that pro-growth changes accumu-
late within a tumor cell and lead to evolution of the most viable
clone.
Glioblastoma (GBM) is the most common malignant brain
tumor of adults (Louis et al., 2007), with poor prognosis regard-
less of treatment (Nicholas, 2007). Amplification of receptor tyro-
sine kinase (RTK) genes plays a crucial role in tumorigenesis ofSignificance
Tumor heterogeneity plays a major role in tumor growth and pr
present a subset of malignant brain tumors with genetic hetero
containing amplification of different receptor tyrosine kinase ge
in the growth of the tumor and that all clones share early gene
Our study provides important insight into the complexity of tum
therapy.
810 Cancer Cell 20, 810–817, December 13, 2011 ª2011 Elsevier IncGBM and is a major driver of tumor growth through activation
of the mitogen-activated protein kinase pathway. Up to 50% of
GBMs have amplification of an RTK, including EGFR, KIT,
VEGFR2, PDGFRA, and MET (Joensuu et al., 2005; Puputti
et al., 2006; Wullich et al., 1993). High-level amplification of
RTK genes appears to be a relatively late event in the tumorigen-
esis of GBM (Attolini et al., 2010), and usually only one RTK
shows high level amplification. We present here a study of malig-
nant human brain tumors in which we examined the distribution
of EGFR, MET, and PDGFRA amplification events in situ to
assess the degree of tumor heterogeneity and to identify tumors
with coamplification of multiple RTKs.
RESULTS
Simultaneous Amplification of Multiple RTKs in GBM
With the purpose of identifying RTKs as possible novel thera-
peutic targets in GBM, we analyzed the Cancer Genome Atlas
project copy number data for amplifications of specific RTKsogression and largely contributes to therapy resistance. We
geneity in the form of intermingled populations of tumor cells
nes.We show that each population is viable and participates
tic changes confirming an origin from a common precursor.
or heterogeneity and has important implications for targeted
.
Figure 1. Data Obtained from Analyses of TCGA Copy Number in GBM
(A) Detailed view of EGFR,MET, and PDGFRA amplification and homozygous deletions of CDKN2A. Cases are arranged so that each column represents single
cases (see Figure S1 for complete receptor tyrosine kinase data).
(B) FISH analysis of TCGA-02-0024 case shows amplification of MET (green) and PDGFRA (red) in the same tumor cells. Scale bar, 20 mm.
Cancer Cell
Mosaic Amplification of Tyrosine Kinases in GBM(Cancer Genome Atlas Research Network, 2008). Out of 206
cases, approximately 50% of GBMs showed amplification of at
least one of the 51 RTKs investigated (Figure S1 available online).
The most commonly amplified RTK gene was EGFR (41% of
the cases) followed by PDGFRA (10%), which is commonly
coamplified with KIT (7% of the cases) and KDR (4% of the
cases) as a part of a single 4q12 amplicon (Joensuu et al.,
2005; Puputti et al., 2006). MET was the third most commonly
amplified RTK (2% of the cases). Seven other RTKs showed
rare amplification limited to <1% of cases. An unexpected
observation was that 13 cases (6.3%) showed coamplification
of multiple RTKs. The most common was coamplification of
EGFR and PDGFRA (five cases). EGFR was simultaneously
coamplified with EPHB3, ERBB3, INSRR, MET, and NTRK1,
each in one case. One case showed coamplification of numerous
RTKs, including EPHA8, EPHB2, FGFR2, and PDGFRA. One
case showed coamplification of MET and PDGFRA. Overall,
EGFR, PDGFRA, andMETwere themost commonly coamplified
RTKs (Figure 1A; Figure S1). To confirm the presence of coampli-
fication, we were able to obtain unstained slides from a single
original TCGA case (TCGA-02-0024) with MET and PDGFRA
amplification, and we performed fluorescence in situ hybridiza-
tion (FISH) for EGFR,MET, and PDGFRA, which showed coam-
plification of PDGFRA and MET within the same tumor cells
(Figure 1B).
Mosaic Amplification of Multiple RTKs within GBM
Due to possible major clinical implications of the coamplification
of multiple RTKs in single tumors, we performed simultaneous
FISH for EGFR,MET, and PDGFRA on our cohort of 350 GBMs.
In total, we have observed 16 GBMs (4.5%) with more than
one amplified RTK. Surprisingly, and unlike TCGA-02-0024,
these multiple RTK amplifications were not present in the same
tumor cell, but were present in distinct intermingled subpopula-
tions of tumor cells (Figure 2). Twelve tumors contained two
distinct subpopulations of tumor cells, each with mutually
exclusive amplification events, including seven tumors with
EGFR and PDGFRA-amplified subpopulations (Figure 2A), threeCantumors with MET and EGFR populations (Figure 2B), and two
tumors with PDGFRA and MET populations (Table S1). Further-
more, four tumors in our study harbored mutually exclusive
amplified subpopulations of all 3 genes EGFR, MET, and
PDGFRA. These distinct subpopulations did not cluster in single
areas, but were intermingled throughout the tumors.
Given the unusual nature of these mosaic tumors, there was
concern that they may in fact represent rare tumors with very
high levels of genome-wide chromosomal instability such as
the recently described chromothripsis phenomenon (Stephens
et al., 2011). In such an instance, multiple amplifications may
represent ‘‘passenger’’ events (i.e., reflect genomic instability
with little impact on the growth of the tumor). We thus employed
a genome-wide copy number assessment (array comparative
genomic hybridization [aCGH]) on three of these mosaic tumors
for which we had DNA of sufficient quantity and quality. In two
cases known to harbor three RTK populations by FISH, we
observed coamplification of only two subpopulations each by
aCGH—EGFR and MET in one (Figure 3A) and PDGFRA and
MET in the other (Figure 3B). A third case showed only EGFR
amplification, failing to detect the expected minor population
of PDGFRA-amplified cells (Figure 3C). Thus, genome-wide
copy number assays are not as sensitive as FISH at detecting
the minor subpopulations. In all three cases analyzed by
aCGH, the amplicons were focal, encompassing only the imme-
diate genomic regions surrounding the genes of interest, and
importantly there was no apparent unusually high level of
genomic instability. We did not detect any other focal amplifica-
tion events involving known cancer genes; however, all three
cases had CDKN2A deletion.
Functionality of Subpopulations with Amplifications
of Different RTK
To further investigate the relevance of these amplification events
for tumor growth, we assessedwhether each subpopulation was
actively proliferating and whether gene amplifications resulted in
overexpression of the corresponding protein. We performed
combined immunofluorescence (IF)-FISH and observed thatcer Cell 20, 810–817, December 13, 2011 ª2011 Elsevier Inc. 811
Figure 2. Mosaic Amplification of RTKs
(A) Two distinct populations of tumor cells with mutually
exclusive amplification of EGFR (red) or PDGFRA (green).
(B) Intermingled subpopulations with mutually exclusive
EGFR (red) or MET (green) amplification.
(C) Expression of MET protein (pink) was limited to cells
withMET amplification (green). EGFR-amplified cells (red)
are negative.
(D and E) Proliferation marker phospho-histone H3 (pink)
highlights proliferating EGFR-amplified (red) cells and
MET-amplified tumor cells (green) in the same tumor (right
panels overlap). Scale bars, 20 mm.
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overexpression of the respective protein only; for example,
tumor cells withMET amplification showed MET overexpression
compared to EGFR-amplified tumor cells, which lacked MET
overexpression (Figure 2C). To prove that each amplified
subpopulation was actively proliferating, we performed IF-FISH
with anti-phospho-histone H3 (M phase marker) antibodies.
Within each tumor, all RTK subpopulations were mitotically
active, as highlighted by the positivity of cells with each of the
possible gene amplifications for phospho-histone H3 expression
(Figures 2D and 2E).
Subpopulations with Different RTK Amplifications
Are Derived from the Same Precursor
Even though each tumor presented clinically as a single brain
mass, we sought to exclude the possibility of a ‘‘collision’’ tumor,
where multiple independent primary tumors are present in the
same anatomic location. To demonstrate that amplified sub-
populations developed from the same precursor, we attempted
to show that within single tumors, the RTK-amplified sub-
populations shared a common early precursor genetic alteration
such as homozygous deletion of CDKN2A or TP53 mutation. In
four tumors, we observed homozygous loss of CDKN2A by
FISH, and importantly, the deletions were in all RTK-amplified
subpopulations, including all three subpopulations in one case
and both subpopulations in three other cases (Figures 4A–4C).
Homozygous CDKN2A loss was also observed by our aCGH
(Figures 3A–3C) as well as in four out of seven TCGA cases
with multiple amplified RTKs (Figure 1B). In seven cases, we
did not observe homozygous deletion in any of the subpopula-
tions. Two of the cases were strongly positive for TP53 protein
expression consistent with TP53 mutation, which was detect-
able by IF-FISH in all amplified subpopulations (Figures 4D and
4E). We completely sequenced TP53 from one of the cases
with sufficient material, which showed that only a single mutation
422 G > A (C141Y) was detectable in the tumor (Figure 4F). In all
cases the CDKN2A and TP53 genotypes were concordant in812 Cancer Cell 20, 810–817, December 13, 2011 ª2011 Elsevier Inc.each of the subpopulations. Statistical analysis
shows that one can reject the null hypothesis
that the subpopulations originated indepen-
dently (i.e., that CDKN2A homozygous dele-
tions and TP53mutations jointly occurred inde-
pendently among subpopulations) (p value,
5.52 3 107). This strongly supports our
hypothesis that subpopulations with differentRTK amplifications are derived from the same precursor, and
thus can be considered subclones.
Microscopic Distribution of Mosaic Subclones
To quantitate the degree of mosaicism of these subclones, we
scored the number of each of four possible cell populations
(EGFR,MET, PDGFRA, or none) (Figure 4G). The ratios of ampli-
fied subclones varied broadly among tumors, with some tumors
showing dominant EGFR, MET, or PDGFRA populations, and
other tumors showing evenly distributed percentages of each.
Although most of the cases in this study were small biopsies,
we had access to a complete brain autopsy for case 8, a patient
with GBM who died untreated 33 days after diagnosis, allowing
us to perform a detailed microscopic analysis of mosaicism
in a single case. The patient presented with a main left parietal
tumor and a second abnormality in the right cingulate gyrus.
Gross examination of the brain showed extensive tumor involve-
ment bilaterally, with a large left parietal mass extending into
the occipital and frontal lobes and the additional right cingulate
mass (Figure 5A). FISH studies of tissue sections showed the
presence of EGFR- and PDGFRA-amplified subclones in an
approximately 60:40 ratio within the main tumor mass (Figures
5B and 5C). However, the infiltrating portion contained exclu-
sively EGFR-amplified cells, which included cells within the
corpus callosum and comprised the entire tumor cell population
of the right cingulate mass (Figures 5D–5F, respectively). EGFR-
amplified cells were again found in the infiltrating edges (Fig-
ure 5G), extending into the grossly normal right temporal
lobe white matter (Figure 5H). Whereas PDGFRA amplified cells
were numerous in the large primary left parietal mass, they were
not found in the infiltrating tumor in either the left or right
hemisphere.
Correlation with Clinical Parameters
For 12 patients, clinical data were available for review. There
was no apparent association with clinico-pathologic param-
eters, including tumor site, sex, age, O6-methylguanine
Figure 3. Selected View of aCGH Analyses (Chromosomes 4, 7, and 9) from Three Cases
(A) No copy number change of PDGFRA, high-level gain of EGFR, and borderline gain of MET.
(B) High-level gain of PDGFRA and MET, but no change for EGFR.
(C) High-level amplification of EGFR, but no change for PDGFRA, which showed amplifcation by FISH. CDKN2A shows homozygous loss in all three cases.
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Mosaic Amplification of Tyrosine Kinases in GBMmethyltransferase (MGMT) status, response to therapy, or
survival (Table S1; Figure S2). The median overall survival was
473 days, which is in line with the expected survival for GBM
patients, though numbers remain too small for definitive conclu-
sions about clinical significance of this finding.
Our findings are limited to GBM; however, we also identified
a case of a salivary duct carcinoma with amplification of
ERBB2 and PDGFRA in separate subclones (Figure S2), which
suggests that the presence of multiple driver genes might not
be unique for GBM but could be a more common and underap-
preciated phenomenon of tumor heterogeneity.
DISCUSSION
We observed an example of tumor genetic heterogeneity in
primary human glioblastomas in which up to three different
focal RTK amplifications define independent clonal populations
possessing proliferative capacity and functional expression of
the corresponding RTK protein. The subclones within each
tumor invariably shared common CDKN2A deletion status or
TP53 status, suggesting that the different RTK populations arose
from a single precursor. These observations have implicationsCanfor our basic understanding of human tumor biology, especially
with regard to clonal evolution, the role of gene amplifications
in this evolutionary process, and the refining of definitions of
tumor driver genes.
Carcinogenesis is an evolutionary process that gives rise to
malignant clones via the process of natural selection and adap-
tation. The fact that genetic/genomic instability is a hallmark of
malignancy (Hanahan and Weinberg, 2011) implies that there is
some degree of genetic heterogeneity in all cancers, and this
intratumor heterogeneity allows for genetic diversity that plays
a crucial role in tumor cell evolution and selection of the clones
with highest proliferative advantage. This is especially important
in the adaptive responses to certain selection pressures such
as hypoxia, metabolic stress, chemotherapy, or radiotherapy
(Gerlinger and Swanton, 2010). Since nearly all of the mosaic
tumors analyzed here were initial biopsies/resections without
prior chemo-radiation, and importantly without exposure to prior
RTK inhibitors, we are probably observing genetic adaptions
that are purely proproliferation or perhaps protective against
metabolic stress.We have previously described tumor heteroge-
neity with respect to EGFR amplification in glioblastoma, where
EGFR-amplified cells are often enriched at the invading edge ofcer Cell 20, 810–817, December 13, 2011 ª2011 Elsevier Inc. 813
Figure 4. Subpopulations with RTK Amplifications
(A–C) All subpopulationswith RTK amplifications share the samemutation and are likely derived from the same precursor. Homozygous loss ofCDKN2A (red) was
seen in tumor cells with RTK amplification (green) in EGFR-amplified (A), MET-amplified (B), and PDGFRA-amplified (C) subpopulations within the same tumor
shown.
(D and E) Both EGFR-amplified (red) and MET-amplified (green) subpopulations (D) show accumulation of TP53 protein (pink), suggesting TP53 mutation
(E, overlap).
(F) Sanger sequencing of the TP53 gene reveals only one mutation (422G>A, C141Y). Forward and reverse tracings are shown.
(G) Ratios of amplified subpopulations in 15 of 16 GBMs with sufficient tissue for quantification. Case numbers 2-4 show three populations of amplified cells, one
EGFR dominant, one PDGFRA dominant, and one MET dominant. Cases 5-11 show variable populations of EGFR- and PDGFRA-amplified cells interspersed
within tumor population with no amplification. Cases 12-14 show tumors with a mixture of EGFR- and MET-amplified subpopulations. Cases 15 and 16 show
a mixture of PDGFRA and MET. Scale bars, 20 mm.
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within a specific niche and suggests that within RTK mosaic
tumors that each of the three populations may be filling distinct
niches within the tumor microenvironment. Thus, whereas the
three subclones are defined by amplification and expression of
the related RTKs EGFR, PDGFRA, and MET, the proteins might
have distinct effects on downstream signaling pathways in each
cell population. The fact that there are no fibroblasts in GBMs
might suggest that the growth and support signals known to
be provided by the tumor stoma in epithelial tumors may them-
selves be provided in GBMs in part by different populations of
tumor cells via paracrine and autocrine signaling.
The coexistence of intermingled functional and actively
dividing EGFR,MET, and PDGFRA-amplified subclones strongly
supports that there is ongoing selection pressure for the growth
of each subclone. The aCGH data indicate that these mosaic
tumors are not characterized by unusually high levels of genomic
instability; nonetheless, we cannot entirely exclude that there is
some stochastic instability at the EGFR, MET, and PDGFRA814 Cancer Cell 20, 810–817, December 13, 2011 ª2011 Elsevier Incloci. The stable coexistence of multiple clones in these tumors
could be explained by near-identical fitness of each of the sub-
clones, which are outgrowing the precursor population but not
outgrowing each other. A more intriguing possibility, however,
is that the selection may be strongest for the population of sub-
clones together as a cooperative group of genetically diverse
clones. This tumor cell-tumor cell interaction can be modeled
as the cooperation of different tumor cells rather than a competi-
tion for the most viable clone (Bach et al., 2001).
The mosaic amplification of RTKs is present in approximately
5% of GBMs, and it is possible that this observation is the tip of
the iceberg in terms of driver gene heterogeneity in cancer. We
suspect that this observation has not been made previously
because of the technical limitations of whole genome copy
number analysis. Although DNA microarrays are effective at
detecting high-level amplification events in pure tumor popula-
tions, as we observed here they will likely have difficulty detect-
ing mosaic populations whose copy number elevations are
diluted out both bymosaic nonamplified cells and contaminating.
Figure 5. Autopsy Study of a Mosaic GBM Case
(A)Magnetic resonance imagingwith contrast shows a large primary tumor with ring enhancement in the left parietal lobe (arrow) and a smaller secondary lesion in
the right cingulate gyrus (arrowhead).
(B and C) The main parietal tumor mass shows a mixture of cells with either EGFR (red) or PDGFRA (green) amplification.
(D and E) The invasive edge of the main tumor (D) and corpus callosum (E) are infiltrated by GBM cells composed exclusively of cells with EGFR amplification.
(F–H) The secondmass in the right cingulate gyrus is also composed of EGFR-amplified cells (F), which infiltrate (G) into the whitematter of the right temporal lobe
(H, arrow). EGFR:PDGFRA subclones in the main tumor mass are in an approximately 60:40 ratio. Colors represent the percentage of EGFR-amplified (red) or
PDGFRA-amplified (green) subclones in each section. Scale bars, 40 mm. See also Figure S2 and Table S1.
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niques are currently the only method to detect such mosaicism
(Navin et al., 2010). However, as techniques for the assessment
of genetic alterations in single cells develop, we will observe
many more examples of this class of tumor (Navin et al., 2011).
Our study raises important issues regarding targeted thera-
pies, including that multiple RTK-targeted therapies may be
required in tumors with mosaic driver gene amplification.
However, if the coexistence of different populations provides
a survival benefit, disrupting any one interaction might collapse
the mutual relationship and thus inhibit the growth of the tumor
overall. EGFR inhibitors have had at best modest efficacy in
GBM patients, and any responses have been unrelated to
EGFR amplification (Nicholas et al., 2011; Yung et al., 2010).
The lack of response is surprising given the very high level of
EGFR amplification in many tumors, and it is possible that
genetic heterogeneity could contribute to this refractoriness.
Our observations underscore the need to clearly define the
use of the term ‘‘driver’’ mutation. Driver mutations in general
can be defined as those that provide a selective growth advan-
tage for tumor cells and are likely good targets for drug develop-
ment (Haber and Settleman, 2007). Drivers can be divided into
early (or tumor initiating) and late (or progression) drivers. Our
observations confirm that loss of CDKN2A (Tunici et al., 2004)Canprecedes high-level amplification of RTKs such as EGFR (Attolini
et al., 2010) and therefore acts as an early driver in primary/de
novo GBM, and would be expected to be present in all tumor
cells. Amplifications of EGFR, PDGFRA, and MET, as progres-
sion drivers, are often heterogeneous within single tumors.
In summary, we describe a unique subtype of human brain
tumor driven by multiple intermixed populations of cells each
with amplification of a different receptor tyrosine kinase. This
observation suggests that RTK amplifications are late events
which are heterogeneously distributed. There are potentially
major implications of mosaic RTK amplification for the develop-
ment of targeted therapies for malignant brain tumors.EXPERIMENTAL PROCEDURES
Patients and Tumor Specimens
Analyses were performed on 350 archival specimens of glioblastoma,
World Health Organization rade IV, seen at the Department of Pathology,
Massachusetts General Hospital, from 2009 to 2011. Approval from the
Dana-Farber/Harvard Cancer Center Institutional Review Board was obtained
prior to the initiation of the study (protocol #2010P002871), and because we
used discarded tissue only, a waiver of informed consent was received.
Formalin-fixed, paraffin-embedded brain biopsy tissues were stained with
routine hematoxylin and eosin stain, and cases were reviewed by two neuro-
pathologists (M.S., D.N.L.). The Cancer Genome Atlas project data werecer Cell 20, 810–817, December 13, 2011 ª2011 Elsevier Inc. 815
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provided by Memorial Sloan-Kettering Cancer Center.
Molecular Analysis
FISH was performed with EGFR (CTD-2113A13 Spectrum Red or Green, Invi-
trogen Nick translation Kit), MET (CTB-1013N12 Spectrum Green, Invitrogen
Nick translation Kit), PDGFRA (RP11-58C6 Spectrum Red or Green, Invitrogen
Nick Translation Kit), CDKN2A (RP11-149I2 Spectrum Red, Invitrogen Nick
translation Kit) probes. In cases where minimum of 1000 tumor cells were
present (cases 2-16), populations with and without amplification were quanti-
fied independently by three observers (L.F., M.S., and B.H.Z.). For indirect IF
staining, we used the following antibodies: mouse anti-EGFR (1:50, Santa
Cruz Biotechnology), rabbit anti-MET (1:100, Abcam), rabbit anti-PDGFR-
alpha (1:100, Abcam), rabbit anti phospho-histone H3 (1:100, Abcam), and
mouse anti-TP53 (1:15, Santa Cruz Biotechnology). Pressure-cooker antigen
retrieval was performed by heating tissue sections in Borg Decloaker solution
(Biocare Medical, Concord, CA) for 3 min followed by cooling sections to room
temperature. Slides were washed and incubated in PBS buffer for 5min. Slides
were then incubated in Avidin D for 20 min, Biotin for 20 min, primary antibody
for 60min, biotinylated secondary antibody for 30min, and streptavidin-conju-
gated fluorophore for 30 min between washes in PBS. Slides were dehydrated
in ethanol and dried in a 65C oven for 5 min. FISH was performed with a mix
of 2-3 probes (3 mL/slide) applied to the slides, followed by denaturation of
the probe and target at 80C for 5 min and overnight hybridization at 37C.
Two 2 min posthybridization washes in 23 SSC were performed with a 72C
water bath and one 1 min wash in 23 SSC was performed at room tempera-
ture. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole. Images
were acquired with an Olympus BX61 fluorescent microscope equipped
with a charge-coupled device camera and analyzed with Cytovision software
(Applied Imaging, Santa Clara, CA).
For aCGH studies, genomic DNA was extracted from formalin-fixed,
paraffin-embedded tissue using the QIAamp Blood Mini Kit using a modified
protocol incorporating deparaffinization and protease digestion (QIAGEN,
Valencia, CA). Genome-wide copy number alterations were analyzed by
array comparative genomic hybridization using the Agilent 4x180k CGH +
SNP microarray (Santa Clara, CA) containing 110,712 copy number probes
covering both coding and noncoding human sequenceswith an overall median
probe spacing of 25.3 kb (5 kb in regions defined by the International
Standards of Cytogenomic Arrays). Briefly, 1.5 mg of NA12891 European
male genomic control DNA (Corriell Institute, Camden, NJ) and 1.5 mg of tumor
DNA were heat-treated at 95C for 5 min. Control and tumor DNAwere labeled
by random priming with CY3 and CY5 deoxyuridine triphosphate dyes,
respectively, using the Agilent Genomic DNA Enzymatic Labeling Kit. The
labeled DNA were purified with the Millipore Amicon 30 kDa centrifugal filter
device (Billerica, MA) and mixed in equal proportion for hybridization to the
array in the presence of Cot-1 DNA (Invitrogen, Carlsbad, CA) using the Agilent
Oligo aCGH Hybridization Kit. Hybridization steps included 3 min denaturation
at 95C, prehybridization for 30 min at 37C, and hybridization for 35-40 hr
at 65C. Following hybridization, the slides were washed with Agilent Oligo
Array CGH Wash Buffer 1 and Buffer 2, at room temperature for 5 min and
at 37C for 1 min, respectively. The slides were washed in acetonitrile (Sigma,
St. Louis, MO) for 10 s. The final wash was performed in Agilent stabilization
and drying solution for 30 s. Washed slides were scanned using the Agilent
G2565CA Microarray Scanner. Microarray TIFF (.tif) images were processed
and analyzed with Agilent CytoGenomics v1.5 software. Copy number aberra-
tion calls were made with a minimum regional absolute average log base 2
ratio of 0.25 and minimum contiguous probe count of 5. All array data were
also manually reviewed for subtle copy number changes not detected by the
software.
Statistical Analysis
We tested our hypothesis that subcloneswithin eachmosaic tumor are derived
from the same precursor versus arising as independent tumors usingCDKN2A
(p16) homozygous deletion and TP53mutation data. The p value is defined to
be the probability of the observed genotype changes, or changes that are
equally as ‘‘extreme,’’ under the assumption of their independence across
subclones and relative to the alternative hypothesis that there is a single event
for each tumor. The observed data that we treated as fixed in the analysis816 Cancer Cell 20, 810–817, December 13, 2011 ª2011 Elsevier Incwere: 13 subjects, 1 with three subclones, 12 with two subclones, and thus
27 subclones, 9 with homozygous p16 deletion only (p16+/TP53), 14 with
no homozygous p16 deletion and no TP53 mutation (p16/TP53), and 4
with TP53mutation only (p16/TP53+). Conditional on these data, the p value
is the probability of observing any assortment of these results such that the
subclones in each subject have the same results, and assuming independence
across all subclones. This simplifies to a hypergeometric probability:

12
3

9
7


27
9

18
14
= 5:523107
The denominator counts the number of ways that the 9 p16+/TP53 sub-
clones can be distributed among the 27 subclones, and the 14 p16/TP53
subclones can be distributed among the 18 remaining subclones (there is
then no choice for placement of the remaining 4 p16/TP53+ clones). The
numerator counts the number of ways the 12 subjects with two clones can
be assigned to the three remaining p16+/TP53 pairs of subclones (note
that the subject with three subclones must be assigned to have all p16+/
TP53 subclones given the observed data) and the remaining 9 subjects
can be assigned to the 7 p16/TP53 pairs of subclones (there is then no
choice for placement of the remaining 2 p16/TP53+ pairs of subclones).
This is equivalent to a 13 3 3 Fisher’s exact test for independence between
subjects and subclones with regard to p16/TP53 status. Survival was esti-
mated using the Kaplan-Meier method.
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